Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

Zymeworks completed its acquisition of Theravance Biopharma, adding the COPD drug YUPELRI, a commercial organization, research assets, collaboration and royalty economics, and Irish tax attributes. The transaction broadens Zymeworks' operating capabilities and adds a marketed respiratory medicine, though no acquisition price or financial contribution was disclosed.